OBJECTIVE: Tumor-stroma ratio (TSR) has been identified as a new and practicable prognostic histological characteristic of solid tumors. The aim of this study was to evaluate the prognostic value of TSR in resected esophageal squamous cell carcinoma (ESCC). METHODS: A total of 95 patients who underwent esophagectomy for ESCC were included in this study. TSR was assessed visually on the hematoxylin-eosin-stained tissue sections of surgical specimens by two independent observers. Patients with more than 50% intratumor stroma were quantified as the stroma-rich group and those with less than 50% as the stroma-poor group. RESULTS: No significant differences were observed in patient, tumor, and treatment characteristics between the stroma-rich and stroma-poor groups. The 3-year overall survival and disease-free survival rates were 64% and 57%, respectively, in the stroma-poor group, and 23% and 23%, respectively, in the stroma-rich group. Both 3-year overall and disease-free survival rates in the stroma-poor group were significantly better than those in the stroma-rich group (p < 0.01). In a multivariate analysis, TSR was identified as a highly significant prognostic factor for 3-year overall survival (hazard ratio 3.450; p = 0.001) and 3-year disease-free survival (hazard ratio 2.995; p = 0.001), independent of pTNM stage and radicality of the primary tumor. CONCLUSION: Stroma-rich tumors were associated with poor prognosis and an increased risk of relapse, which may serve as a new prognostic histological characteristic in ESCC. TSR is simple and quick to determine, is reproducible, and could be easily incorporated in routine histological evaluation.
OBJECTIVE:Tumor-stroma ratio (TSR) has been identified as a new and practicable prognostic histological characteristic of solid tumors. The aim of this study was to evaluate the prognostic value of TSR in resected esophageal squamous cell carcinoma (ESCC). METHODS: A total of 95 patients who underwent esophagectomy for ESCC were included in this study. TSR was assessed visually on the hematoxylin-eosin-stained tissue sections of surgical specimens by two independent observers. Patients with more than 50% intratumor stroma were quantified as the stroma-rich group and those with less than 50% as the stroma-poor group. RESULTS: No significant differences were observed in patient, tumor, and treatment characteristics between the stroma-rich and stroma-poor groups. The 3-year overall survival and disease-free survival rates were 64% and 57%, respectively, in the stroma-poor group, and 23% and 23%, respectively, in the stroma-rich group. Both 3-year overall and disease-free survival rates in the stroma-poor group were significantly better than those in the stroma-rich group (p < 0.01). In a multivariate analysis, TSR was identified as a highly significant prognostic factor for 3-year overall survival (hazard ratio 3.450; p = 0.001) and 3-year disease-free survival (hazard ratio 2.995; p = 0.001), independent of pTNM stage and radicality of the primary tumor. CONCLUSION:Stroma-rich tumors were associated with poor prognosis and an increased risk of relapse, which may serve as a new prognostic histological characteristic in ESCC. TSR is simple and quick to determine, is reproducible, and could be easily incorporated in routine histological evaluation.
Authors: Lorenzo Preda; Giorgio Conte; Luke Bonello; Caterina Giannitto; Laura L Travaini; Sara Raimondi; Paul E Summers; Ansarin Mohssen; Daniela Alterio; Maria Cossu Rocca; Chiara Grana; Francesca Ruju; Massimo Bellomi Journal: Eur Radiol Date: 2016-03-10 Impact factor: 5.315
Authors: Raghu Kadaba; Hanna Birke; Jun Wang; Steven Hooper; Claudia D Andl; Francesco Di Maggio; Erdinc Soylu; Mohammed Ghallab; Daniel Bor; Fieke Em Froeling; Satyajit Bhattacharya; Anil K Rustgi; Erik Sahai; Claude Chelala; Peter Sasieni; Hemant M Kocher Journal: J Pathol Date: 2013-03-21 Impact factor: 7.996
Authors: Cole R Drifka; Jo Tod; Agnes G Loeffler; Yuming Liu; Gareth J Thomas; Kevin W Eliceiri; W John Kao Journal: Mod Pathol Date: 2015-09-04 Impact factor: 7.842
Authors: Sarah Ouahoud; Philip W Voorneveld; Lukas J A C Hawinkels; James C H Hardwick; Lennart R A van der Burg; Eveline S M de Jonge-Muller; Mark J A Schoonderwoerd; Madelon Paauwe; Thijs de Vos; Sophie de Wit; Gabi W van Pelt; Wilma E Mesker Journal: Oncogene Date: 2020-01-23 Impact factor: 9.867